Galectin Therapeutics, Inc. (GALT)
3.89
+0.18
(+4.85%)
USD |
NASDAQ |
Sep 18, 16:00
3.89
0.00 (0.00%)
After-Hours: 20:00
Galectin Therapeutics Free Cash Flow : -15.89M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -15.89M |
| March 31, 2026 | -20.05M |
| December 31, 2025 | -23.88M |
| September 30, 2025 | -30.62M |
| June 30, 2025 | -35.62M |
| March 31, 2025 | -37.35M |
| December 31, 2024 | -41.77M |
| September 30, 2024 | -33.68M |
| June 30, 2024 | -32.78M |
| March 31, 2024 | -34.28M |
| December 31, 2023 | -32.96M |
| September 30, 2023 | -35.50M |
| June 30, 2023 | -36.21M |
| March 31, 2023 | -33.81M |
| December 31, 2022 | -31.06M |
| September 30, 2022 | -30.77M |
| June 30, 2022 | -27.42M |
| March 31, 2022 | -25.97M |
| December 31, 2021 | -24.31M |
| September 30, 2021 | -22.77M |
| June 30, 2021 | -25.98M |
| March 31, 2021 | -22.61M |
| December 31, 2020 | -20.60M |
| September 30, 2020 | -18.95M |
| June 30, 2020 | -12.21M |
| Date | Value |
|---|---|
| March 31, 2020 | -11.94M |
| December 31, 2019 | -10.85M |
| September 30, 2019 | -9.096M |
| June 30, 2019 | -9.198M |
| March 31, 2019 | -9.947M |
| December 31, 2018 | -10.18M |
| September 30, 2018 | -12.08M |
| June 30, 2018 | -13.62M |
| March 31, 2018 | -15.54M |
| December 31, 2017 | -15.89M |
| September 30, 2017 | -16.85M |
| June 30, 2017 | -17.17M |
| March 31, 2017 | -16.78M |
| December 31, 2016 | -16.41M |
| September 30, 2016 | -16.14M |
| June 30, 2016 | -17.78M |
| March 31, 2016 | -16.16M |
| December 31, 2015 | -16.98M |
| September 30, 2015 | -15.50M |
| June 30, 2015 | -13.69M |
| March 31, 2015 | -13.12M |
| December 31, 2014 | -12.43M |
| September 30, 2014 | -10.96M |
| June 30, 2014 | -9.16M |
| March 31, 2014 | -8.68M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Mirum Pharmaceuticals, Inc. | -263.74M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
| Savara, Inc. | -110.66M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.439M |
| Cash from Financing (Quarterly) | 1.597M |
| Free Cash Flow Per Share (Quarterly) | -0.037 |
| Free Cash Flow to Equity (Quarterly) | -4.484M |
| Free Cash Flow to Firm (Quarterly) | -0.435M |
| Free Cash Flow Yield | -6.26% |